

BEST AVAILABLE COPY

DARBY &  
DARBYRECEIVED  
CENTRAL FAX CENTER

MAY 27 2005

805 Third Avenue  
New York, NY 10022  
Tel: (212) 527-7700  
Fax: (212) 753-6237

E-MAIL:

FILE #: 02427/00E986-USDATE: 5/27/05NUMBER TRANSMITTING TO: 703-746-9195RECIPIENT: O I P ECOMPANY: United States Patent and Trademark OfficeFROM: Elynn BarrisonNO. OF PAGES TRANSMITTING  
(INCLUDING COVER SHEET)\*: 8CONFIRMATION OF THIS TRANSMISSION WILL FOLLOW BY  
FIRST CLASS MAIL (Y/N): NO

COMMENTS:

THE INFORMATION CONTAINED IN THIS FACSIMILE MESSAGE IS INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY NAMED ABOVE. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT, OR THE EMPLOYEE OR AGENT RESPONSIBLE TO DELIVER IT TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION, DISTRIBUTION OR COPYING OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE IMMEDIATELY NOTIFY US BY TELEPHONE SO THAT WE CAN ARRANGE FOR THE RETRIEVAL OF THIS DOCUMENT AT NO COST TO YOU. THANK YOU.

PLEASE RETURN TO

*Julian Williams*

\* IF YOU DO NOT RECEIVE ALL PAGES, PLEASE TELEPHONE US IMMEDIATELY AT (212) 527-7774

**BEST AVAILABLE COPY****RECEIVED  
CENTRAL FAX CENTER****MAY 27 2005****CERTIFICATE OF FACSIMILE TRANSMISSION**

I hereby certify that this paper or, if this paper is a transmittal letter, every other paper or fee referred to therein, is being facsimile transferred to the Commissioner for Patents & Trademarks at the United States Patent and Trademark Office, Alexandria, VA 22313-1450, at 703-308-7781 on the date shown below.

PLEASE CHARGE ANY DEFICIENCY UP TO \$300.00 OR CREDIT ANY EXCESS IN THE FEES DUE WITH THIS DOCUMENT TO OUR DEPOSIT ACCOUNT NO. 04-0100

5/27/05 Suljo Williams  
Date Name  
Suljo Williams  
Signature

Customer No.: 07278

Docket No.: 02427/100E988-US1

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Vincent J. Kidd et. al.

Serial No.: 09/477,082

Filed: December 30, 1999

For: A TUMOR SUPPRESSOR PROTEIN INVOLVED IN DEATH SIGNALLING, AND  
DIAGNOSTICS THERAPEUTICS, AND SCREENING BASED ON THIS PROTEIN

**REQUEST FOR CORRECTED FILING RECEIPT**

Commissioner of Patents and Trademarks  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

1. Attached is a copy of the official filing receipt received from the PTO in the above application for which issuance of a corrected filing receipt is respectfully requested.
2. There is an error with respect to the following data, which is:

- ☒ incorrectly entered and/or  
☐ omitted.

{W:\02427\100e988us1\00440777.DOC [REDACTED]}

**BEST AVAILABLE COPY**

<b>Error in</b>	<b>Correct data</b>
<input checked="" type="checkbox"/> Applicant's name	Vincent J. Kidd, Memphis, TN Jill M. Lahti, Memphis, TN Tal Teltz, Cordova, TN
<input type="checkbox"/> Applicant's address	
<input type="checkbox"/> Title	
<input type="checkbox"/> Filing Date	
<input type="checkbox"/> Application Number	
<input type="checkbox"/> Foreign/PCT Application Re:	
<input type="checkbox"/> Other	

**Remarks:**

Enclosed please find a copy of the Executed Declaration.

The Commissioner is respectfully requested to issue a new and correct Filing Receipt.

Respectfully submitted,

Dated: May 26, 2005



Flynn Barrison  
Reg. No. 53,970  
Agent for Applicant(s)

DARBY & DARBY P.C.  
P.O. Box 5257  
New York, New York 10150-5257  
212-527-7700

{W:\02427\100e988us1\00440777.DOC 000000000000000000 }

**BEST AVAILABLE COPY** <http://www.uspto.gov/ip/program/correspondence/1.htm>**FILING RECEIPT**

\*OC00000005043842\*

**UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office**Address: ASSISTANT SECRETARY AND  
COMMISSIONER OF PATENT AND TRADEMARKS  
Washington, D.C. 20231

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/477,082	12/30/1999	1643	848	2427/IE988-U	14	47	8

DARBY & DARBY  
805 THIRD AVE  
NEW YORK, NY 10022

Date Mailed: 04/11/2000

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of this examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

**Applicant(s)**VINCENT J. KIDD, MEMPHIS, TN;  
JILL M. LAHTI, MEMPHIS, TN;  
TARTEITZ, CORDOVA, TN;**Continuing Data as Claimed by Applicant**

THIS APPLN CLAIMS BENEFIT OF 60/114,308 12/31/1998

**Foreign Applications**

If Required, Foreign Filing License Granted 02/09/2000

\*\* SMALL ENTITY \*\*

**Title**TUMOR SUPPRESSOR PROTEIN INVOLVED IN DEATH SIGNALING, AND DIAGNOSTICS,  
THERAPEUTICS, AND SCREENING BASED ON THIS PROTEIN**Preliminary Class**

536

Data entry by : BRUNSON, MONIQUE

Team : OIPE

Date: 04/11/2000

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100

**BEST AVAILABLE COPY**

file:///c:/KPS/procxam/correspondence/1.htm

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.63(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

**PLEASE NOTE the following information about the Filing Receipt:**

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents  
Office of Initial Patent Examination  
Customer Service Center  
Washington, DC 20231